What Is TB-500? Definition and What Research Reports
TB-500 is a research label for a synthetic peptide based on thymosin β4 (Tβ4), a small naturally occurring peptide found across mammalian tissues. The phrase "BPC TB-500 blend" is not a product name or a single molecule; it describes TB-500 discussed or tested alongside BPC-157, an unrelated peptide sequence. Published work on Tβ4 is largely preclinical, spanning tendon, wound, eye, ear, liver and neurological models, with separate literature examining Tβ4 in tumour biology.
Definition
TB-500 is a research name used for a synthetic peptide based on thymosin β4 (Tβ4), a small naturally occurring peptide found in many mammalian tissues and body fluids; a 2012 review characterised Tβ4 as a multi-functional regenerative peptide and surveyed its basic properties and clinical applications (PMID 22074294). The phrase "BPC TB-500 blend" is not the name of an approved medicine, a single molecule, or a standardised laboratory reagent. It is informal shorthand for TB-500 being discussed, prepared or tested alongside BPC-157, a structurally unrelated peptide sequence, as occurred in a 2026 rat study that assessed BPC-157 and TB-500 in Achilles tendon healing using histopathological and biomechanical outcomes (PMID 42542926). This entry is definitional: it explains what the words refer to and what the cited literature reports, and nothing more. This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question.
What Class of Molecule Is It?
Tβ4 is a peptide — a short chain of amino acids — rather than a small-molecule drug, a steroid, or a hormone in the classical endocrine sense. Peptides of this type are manufactured either by chemical synthesis or by recombinant expression in cells. Recombinant human Tβ4 (rhTβ4) was the preparation used in a 2021 study in seborrheic dermatitis, where researchers reported improved scalp condition and microbiome homeostasis (PMID 34318587). Because the source material can be synthetic or recombinant, the label on a research vial describes a manufacturing route, not an approval status.
Thymosin β4 sequences are not unique to humans. Comparative work reported that thymosin β4 participates in antibacterial immunity and wound healing in the black tiger shrimp, Penaeus monodon (PMID 37689229), which is one reason the peptide family is described as evolutionarily conserved in the literature.
How the Term Is Used in Peptide Research
Three distinct usages appear in writing about this compound, and they are frequently conflated:
- Thymosin β4 (Tβ4) — the endogenous peptide studied in the peer-reviewed literature. Almost all published data use this name, not "TB-500".
- TB-500 — a research/product-style label applied to synthetic Tβ4-related material. It appears in a small number of animal papers, including the 2026 Achilles tendon study in rats that tested it alongside BPC-157 (PMID 42542926).
- "BPC TB-500 blend" — informal terminology for the two peptides considered together. It is not an established pharmacological classification, and the combination has not been characterised in the verified literature beyond the rat tendon model cited above.
For reference purposes, readers encountering the phrase should treat it as descriptive of a pairing, not as evidence that the pairing has been formally studied as a defined preparation.
| Term | What it refers to |
|---|---|
| Thymosin β4 (Tβ4) | The naturally occurring peptide used as the subject name in most published research |
| rhTβ4 | Recombinant human thymosin β4, a laboratory-produced version used in some studies |
| TB-500 | Research-style label for synthetic Tβ4-related peptide material |
| BPC-157 | A separate, unrelated peptide sequence sometimes examined in the same experiments |
| "Blend" | Informal shorthand for two peptides discussed or prepared together; not a pharmacological class |
Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.
Try it freeWhat the Published Literature Reports
Tendon and musculoskeletal models
The most directly relevant paper to the paired terminology is the 2026 rat study, in which researchers evaluated the effects of BPC-157 and TB-500 on Achilles tendon healing using histopathological and biomechanical assessment (PMID 42542926). It was an animal model, not a human trial, and its outcomes describe tissue and mechanical measurements in rats rather than clinical endpoints in people.
Wound, skin, eye and ear models
A larger share of the Tβ4 literature concerns tissue repair. A 2021 study reported that recombinant human Tβ4 improved scalp condition and microbiome homeostasis in seborrheic dermatitis (PMID 34318587). Researchers examined Tβ4 as a potential adjunct treatment for bacterial keratitis, an infectious corneal condition (PMID 37018981), and separately described Tβ4 as a potential tool in healing middle ear lesions in adult mammals (PMID 38706788). A 2026 bioengineering study did not deliver the peptide on its own but used sprayable bioadhesive microcarriers loaded with Tβ4-engineered adipose-derived stem cell exosomes in a diabetic wound-healing model (PMID 42383202), illustrating that much current work focuses on delivery systems rather than the free peptide.
Liver and metabolic models
In liver research, one study reported that thymosin β4 alleviated non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 (PMID 34280397), while earlier work reported that thymosin β4 regulates activation of hepatic stellate cells via hedgehog signalling (PMID 28630423). Both are mechanistic, preclinical investigations of signalling pathways.
Neurological models
A 2025 study used human brain organoids and identified thymosin β4 as an Alzheimer disease intervention target (PMID 40816274). Organoid work of this kind is a laboratory discovery method and does not describe outcomes in patients.
Tumour Biology and Other Signals: What Studies Report
The verified literature summarised here does not contain a human adverse-event dataset for TB-500 or for any BPC-157 pairing, so no safety profile can be stated from it. What the literature does contain is a separate strand of tumour-biology research. An older paper described the localization of thymosin β4 in tumors (PMID 17495241), and a 2025 mechanistic study examined the Tβ4/SLC7A11 signalling pathway in the regulation of breast cancer evolution (PMID 40912522). Those reports concern the endogenous peptide's role in cancer biology rather than the administration of a synthetic analogue, but they are part of why Tβ4 is described in reviews as multi-functional rather than narrowly regenerative (PMID 22074294).
Tracking research? Log entries with dates, lots and notes — records, never plans.
Get the appRegulatory and Reference Notes
TB-500 is not an approved medicine in the United States, and material sold under that label is typically designated research use only (RUO), meaning it is not intended for human or veterinary administration. "BPC TB-500 blend" has no regulatory definition at all. Readers using this entry as a reference should note the distinction between the extensively studied endogenous peptide thymosin β4, the recombinant preparation rhTβ4 used in specific studies such as the seborrheic dermatitis work (PMID 34318587), and the informal research label TB-500. This page is for educational purposes only and is not medical advice; consult a licensed physician before considering any intervention.
References
- Thymosin β4: a multi-functional regenerative peptide. Basic properties and clinical applications (Expert Opinion on Biological Therapy, 2012)
- Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study (Joint Diseases and Related Surgery, 2026)
- Recombinant human thymosin beta-4 (rhTβ4) improved scalp condition and microbiome homeostasis in seborrheic dermatitis (Microbial Biotechnology, 2021)
- Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis (International Immunopharmacology, 2023)
- Thymosin beta-4 - A potential tool in healing middle ear lesions in adult mammals (International Immunopharmacology, 2023)
- Sprayable bioadhesive microcarriers loaded with Tβ4-Engineered ADSC exosomes for diabetic wound healing (Bioactive Materials, 2026)
- Thymosin beta 4 alleviates non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 (European Journal of Pharmacology, 2021)
- Thymosin beta-4 regulates activation of hepatic stellate cells via hedgehog signaling (Scientific Reports, 2017)
- Thymosin beta 4 as an Alzheimer disease intervention target identified using human brain organoids (Stem Cell Reports, 2025)
- Mechanistic study of the Tβ4/SLC7A11 signaling pathway regulating breast cancer evolution (Cellular Signalling, 2025)
- Localization of thymosin beta-4 in tumors (Annals of the New York Academy of Sciences, 2007)
- Thymosin beta-4 participate in antibacterial immunity and wound healing in black tiger shrimp, Penaeus monodon (Fish & Shellfish Immunology, 2023)
Frequently asked questions
What does "BPC TB-500 blend" actually mean?▾
It is informal shorthand for TB-500 being discussed or prepared together with BPC-157, a structurally unrelated peptide. It is not an approved product, a defined molecule, or a pharmacological class. The pairing appears in a 2026 rat study that assessed both compounds in Achilles tendon healing using histopathological and biomechanical outcomes (PMID 42542926).
Is TB-500 the same thing as thymosin beta 4?▾
Not exactly. Thymosin β4 is the naturally occurring peptide used as the subject name in nearly all published research, including a 2012 review that described it as a multi-functional regenerative peptide and surveyed its basic properties and clinical applications (PMID 22074294). TB-500 is a research-style label applied to synthetic Tβ4-related material rather than a formal scientific name.
What kind of molecule is TB-500?▾
It is a peptide, meaning a short chain of amino acids, rather than a steroid or small-molecule drug. Such peptides are made by chemical synthesis or recombinant expression; recombinant human Tβ4 was the preparation used in a 2021 study that reported improved scalp condition and microbiome homeostasis in seborrheic dermatitis (PMID 34318587).
What areas has thymosin beta 4 research covered?▾
Published work spans tissue repair and several organ systems. Researchers examined Tβ4 as a potential adjunct in bacterial keratitis (PMID 37018981) and as a potential tool in healing middle ear lesions in adult mammals (PMID 38706788). Liver work reported that Tβ4 alleviated non-alcoholic fatty liver by inhibiting ferroptosis via up-regulation of GPX4 (PMID 34280397).
Does the literature link thymosin beta 4 to cancer biology?▾
A separate research strand exists. One paper described the localization of thymosin β4 in tumors (PMID 17495241), and a 2025 mechanistic study examined the Tβ4/SLC7A11 signalling pathway in the regulation of breast cancer evolution (PMID 40912522). These reports concern the endogenous peptide's biology, not administration of a synthetic analogue.
Are there human clinical trials of TB-500?▾
The verified literature summarised on this page is predominantly preclinical: animal models, cell and organoid systems, and delivery-engineering work such as sprayable microcarriers loaded with Tβ4-engineered exosomes in a diabetic wound model (PMID 42383202). A 2025 study identified Tβ4 as an Alzheimer disease intervention target using human brain organoids (PMID 40816274), which is a laboratory discovery method.
Is thymosin beta 4 found only in humans?▾
No. The peptide family is described as evolutionarily conserved. Comparative research reported that thymosin β4 participates in antibacterial immunity and wound healing in the black tiger shrimp, Penaeus monodon (PMID 37689229). In mammals, a 2012 review summarised the peptide's distribution and basic properties alongside its reported clinical applications (PMID 22074294).
Track it. Calculate it. Actually understand it.
References
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.